JUST IN: The FDA has approved Isembyld, the first treatment for spinal muscular atrophy designed to target the muscle itself, rather than the underlying genetic cause. It blocks myostatin, a protein that normally limits muscle growth
JUST IN: Gen Zโs daytime parties are getting a wellness makeover. Some events are swapping alcohol for run clubs, cold plunges and functional drinks, basically turning fitness and recovery into the social activity itself.
JUST IN: A new study suggests AI can pull much more heart-failure information from a standard ECG than doctors normally get from the test alone. In more than 8,000 patients, the AI score tracked with structural and functional heart problems seen on ultrasound.
JUST IN: GLP-1 drugs are moving further beyond weight loss. New heart-failure guidance now recommends semaglutide or tirzepatide for some people with obesity and heart failure with preserved ejection fraction.
JUST IN: Microplastics were detected in 84% of patients having a major heart attack in a small new study, compared with 32% of people with healthy coronary arteries.